



# Association of Cycle Threshold (Ct) Values of SARS-CoV-2 RT-PCR with Disease Severity and Symptoms among COVID-19 Patients in Ghadamis, Libya

## ARTICLE INFO

### Article Type Original Article

#### Authors

Ghassan Tayh, *PhD*<sup>1\*</sup>  
Asma Elramli, *MSc*<sup>2</sup>  
Siham R Agouri, *PhD*<sup>3</sup>  
Elmundr Abughnia, *MSc*<sup>4</sup>  
Naïla Y Abdulrahman, *MSc*<sup>5</sup>  
Abdulhafar A Shihab, *MSc*<sup>6</sup>  
Hafsa A Alemam, *MSc*<sup>7</sup>

<sup>1</sup> Department of Microbiology and Immunology, National School of Veterinary Medicine, University of Manouba, LR16AGR01, 2020 Sidi Thabet, Ariana, Tunisia

<sup>2</sup> Department of Medical Technology, College of Science and Technology - Qaminis, Benghazi, Libya

<sup>3</sup> Department of Microbiology, Faculty of Science, University of Benghazi, Libya.

<sup>4</sup> Department Tissue culture plant at Libya Center for Biotechnology Research, Tripoli, Libya.

<sup>5</sup> Head of internal medical department in Ghadamis general hospital, Libya.

<sup>6</sup> National Center of Disease Control (NCDC) Ghadmes, Libya

<sup>7</sup> Department of Environment food, and Biological Application, at Libya Center for Biotechnology Research, Tripoli, Libya.

#### \* Correspondence

Department of Microbiology and Immunology, National School of Veterinary Medicine, University of Manouba, LR16AGR01, 2020 Sidi Thabet, Ariana, Tunisia. E-mail: ghassan.tayh@fst.utm.tn

#### How to cite this article

Tayh Gh., Elramli A., Agouri S.R., Abughnia E., Abdulrahman N.Y., Shihab A.A., Alemam H.A. Association of Cycle Threshold (Ct) Values of SARS-CoV-2 RT-PCR with Disease Severity and Symptoms among COVID-19 Patients in Ghadamis, Libya. *Infection Epidemiology and Microbiology*. 2024;10(4): 309-317.

#### Article History

Received: June 30, 2024

Accepted: November 22, 2024

Published: December 20, 2024

## ABSTRACT

**Background:** This study aimed to assess the relationship between cycle threshold (Ct) values and disease severity, symptoms, and comorbidities in COVID-19-positive individuals.

**Materials & Methods:** This cross-sectional study was conducted on COVID-19 patients who were admitted to General Ghadamis hospital and diagnosed with COVID-19 from August 2020 to 2021. The association between Ct values and symptoms, demographic characteristics, and clinical characteristics was analyzed by SPSS analysis.

**Findings:** A total of 286 patients were included in this study, of whom 53.5% were female, and 46.5% were male, with a median age of 53 years (range: 1–90 years). Among symptomatic individuals, 51.4% had severe COVID-19 symptoms, and 26.6% had mild symptoms. Severe systemic symptoms were significantly associated with older age groups. The majority of elderly patients (66%) exhibited low Ct values (Ct ≤ 24), indicating a high viral load. Additionally, 64.6 and 40.8% of patients with severe and mild symptoms had low Ct values. Symptoms varied significantly across patients with low, medium, and high Ct values. There was a strong correlation between lower Ct values and the presence of comorbidities such as hypertension, diabetes mellitus, ischemic heart disease (IHD), cerebrovascular accident, and cancer.

**Conclusion:** Compared to asymptomatic individuals, most symptomatic patients with severe and mild symptoms had significantly lower Ct values. These findings highlight the critical role of viral load in SARS-CoV-2 progression and suggest that Ct values could be used to predict the spread of infection in the community.

**Keywords:** SARS-CoV-2, COVID-19, COVID-19 severity, Comorbidities, Viral load, Coronavirus infections, Infection severity

## CITATION LINKS

[1] Pang J, et al. Potential rapid... [2] Machado BAS, The main molecular and... [3] Shenoy S. SARS-CoV-2 (COVID-19), viral load and... [4] Magleby R, et al. Impact of severe acute respiratory... [5] Ramirez-Hinojosa JP, et al. Association between cycle threshold... [6] Waudby-West R, The association between SARS-CoV-2 ... [7] Shah VP, et al. Association between SARS-CoV-2... [8] Sala E, Systematic review on the correlation between... [9] Yin N, et al. Leveraging of SARS-CoV-2... [10] Penney JA, Utility of the cycle threshold in anticipating... [11] Lippi G, Plebani M. The many clinical advantages of... [12] WHO. Libya COVID-19 Surveillance Weekly Bulletin... [13] George A, Epidemiology of COVID-19 and the Utility of... [14] Wells PM, et al. Estimates of the rate... [15] Li Y, et al. Asymptomatic and symptomatic... [16] Al-Rifai RH, et al. Epidemiological characterization of... [17] Yagci AK, et al. Relationship of the cycle ... [18] Kleiboeker S, et al. SARS-CoV-2 viral load... [19] Rao SN, A narrative systematic review of the... [20] Li Z, et al. Differentiating pneumonia with... [21] Wu Z, McGoogan JM. Characteristics of and important ... [22] Maltezou HC, et al. Association between upper respiratory... [23] To KK-W, et al. Temporal profiles of viral... [24] Abdulrahman A, Association between RT-PCR Ct... [25] Kociolek LK, et al. Comparison of upper respiratory viral load... [26] Han MS, et al. Viral RNA load in mildly... [27] Wu C, et al. Risk factors associated with acute... [28] Liang W, et al. Cancer patients in SARS-CoV-2...

## Introduction

Since the onset of the COVID-19 (coronavirus disease 2019) pandemic, the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA gene sequences by reverse transcription polymerase chain reaction (rRT-PCR) has been the primary method for SARS-CoV-2 detection [1]. Real-time RT-PCR, a molecular diagnostic technique that uses thermocycling to amplify viral nucleic acid, is considered the gold standard method for COVID-19 diagnosis [2].

While this analysis typically provides a qualitative result for viral presence, it also yields cycle threshold (Ct) values to end users. The Ct value refers to the number of amplification cycles required for the fluorescence of a specific gene target to exceed a predetermined detection threshold level [3].

Ct values offer an indirect measure of the number of viral ribonucleic acid (RNA) copies present in a sample [2]. rRT-PCR tests generally inform clinicians only of the presence or absence of SARS-CoV-2. However, these assays also provide quantitative data on Ct values, which are inversely related to viral load and carry significant clinical implications [4].

Several studies have reported a correlation between lower Ct values and increased illness severity, with Ct values in SARS-CoV-2 RT-PCR serving as a marker for COVID-19 severity [5, 6]. Ct values could encourage

decisions about patient care, infection prevention, and public health [7].

Lower Ct values are strongly associated with symptomatic COVID-19, indicating higher viral load and longer duration of viral shedding, both of which may affect the spread and transmissibility of the disease [8]. It is now evident that Ct values are an important marker for the development and incidence of local SARS-CoV-2 outbreaks. Studies have shown that trends in Ct values reflect epidemic trajectories and could predict COVID-19-related hospitalizations [9, 10]. In addition to these significant epidemiological insights, accumulating evidence suggests that regular monitoring of SARS-CoV-2 Ct values using precise and standardized molecular assays could have significant clinical implications [11].

Despite the proven association of Ct values with COVID-19 infection outcomes, there is currently no consensus on the clinical utility of SARS-CoV-2 Ct values. The role of Ct levels in understanding the spectrum of symptoms remain unclear.

**Objectives:** This study aimed to evaluate the accuracy of Ct values and determine the association between Ct values and symptoms, disease severity, and comorbidities among COVID-19-positive cases in Libya.

## Materials and Methods

This cross-sectional study was conducted in the Molecular Biology Department of Ghadamis hospital in Ghadamis city

**Table 1)** shows the primer and probe sequences used in real-time RT-PCR to detect SARS-CoV-2.

| Assay/ Use | Oligonucleotide ID | Sequence (5`-3`)                  |
|------------|--------------------|-----------------------------------|
| RdRP       | RdRP_SARsR-F2      | GTGARATGGTCATGTGTGGCGG            |
|            | RdRP_SARsR-R1      | CARATGTTAAASACACTATTAGCATA        |
|            | RdRP_SARsR-P2      | FAM-CAGGTGGAACCTCATCAGGAGATGCBBQ  |
|            | RdRP_SARsR-P1      | FAMCCAGGTGGWACRTCATCMGGTGATGCBBQ  |
| E gene     | E_Sarbeco_F1       | ACAGGTACGTTAATAGTTAATAGCGT        |
|            | E_Sarbeco_R2       | ATATTGCAGCAGTACGCACACA            |
|            | E_Sarbeco_P1       | FAM-ACACTAGCCATCCTTACTGCGCTTCGBBQ |

(western Libya) from August 2020 to August 2021. Samples from all patients admitted to various clinical departments of General Ghadamis hospital and confirmed as COVID-19 cases by Cepheid® GeneXpert real-time PCR instrument were included in this study.

Data of all COVID-19 patients were collected from their hospital records, including information on gender, age, diagnosis, and clinical data. Ct values of COVID-19-positive samples collected during the one-year study period were evaluated. For detection, reverse transcription polymerase chain reaction (RT-PCR) was employed. The collected samples were subjected to Phoenix Dx 2019-nCoV assay, a real-time RT-PCR-based test designed for the in vitro qualitative detection of 2019-novel coronavirus (2019-nCoV) in respiratory and serum samples (Rotor-gene – QIAGEN). Specific primer and probe sets were designed for 2019-nCoV detection following the latest CDC (Centers for Disease Control and Prevention) and WHO (World Health Organization) guidelines.

A 25- $\mu$ L reaction mixture was prepared, containing 5  $\mu$ L of RNA, 12.5  $\mu$ L of 2X reaction buffer from the Superscript III One-Step RT-PCR System with Platinum Taq Polymerase (Invitrogen; containing 0.4 mM of each deoxyribonucleotide triphosphates and 3.2 mM magnesium sulfate), 1  $\mu$ L of reverse transcriptase/Taq mixture from the kit, 0.4  $\mu$ L of 50 mM magnesium sulfate solution (Invitrogen – not provided with the kit), and 1  $\mu$ g of nonacetylated bovine serum albumin (Roche). All oligonucleotides were synthesized and provided by Tib-Molbiol, Berlin. Thermal cycling was carried out at 55 °C for 10 min for reverse transcription, followed by one cycle of 95 °C for 3 min and then 45 cycles of 95 °C for 15 seconds and 58 °C for 30 seconds.

Ct values were evaluated based on different age groups, gender, history of chronic

diseases, and clinical symptoms of COVID-19 patients. Ct values above 30, between 25 and 30, and below 25 were grouped as low, moderate, and high viral load, respectively. The COVID-19 disease was classified based on its symptoms and severity according to the WHO as follows: mild cases typically involve fever, cough, and fatigue; moderate cases may include difficulty breathing or mild pneumonia; and severe cases may have severe pneumonia, other organ failure, and possibly death.

**Statistical analysis:** The collected data were tabulated and analyzed using IBM SPSS Statistics for Windows, Version 19 software (IBM Corporation, Somers, NY). Significant differences in the association between variables were assessed using Pearson's Chi-square test, with the level of statistical significance set at  $p < .05$ .

### Findings

This study included a total of 286 COVID-19-positive patients, of whom 153 (53.5%) were female, and 133 (46.5%) were male. The age of the studied patients ranged from one year to 90 years with a median age of 53 years. Most of the patients were in the age group of 41-60 years ( $n=166$ , 58.1%), followed by the age groups of 18-40 ( $n=61$ , 21.3%) and  $\geq 61$  ( $n=53$ , 18.5%) years, respectively. The pediatric group was the least affected group as shown in Table 2.


The majority of examined patients (78%) were symptomatic, 51.4% had severe symptoms, and 26.6% had moderate (mild) symptoms. Meanwhile, 22% of the patients were asymptomatic (Figure 1).

Among the 286 COVID-19 patients included in this study, 72.7% ( $n=208$ ) had comorbidities, with asthma, diabetes mellitus, and hypertension being the most prevalent underlying conditions (Table 3). Two-thirds of the pediatric population were asymptomatic, while around 70-85%

of patients in the other age groups were symptomatic. Severe systemic symptoms were the most common in the age groups of  $\geq 61$  (75.5%) and 41-60 (50%) years, respectively. These differences were statistically significant ( $p < .000$ ) (Figure 2). By comparing the severity of symptoms between patients with chronic comorbidities, it was found that the majority of severe cases occurred in patients with chronic conditions. Conversely, a large proportion of patients without chronic conditions (66.7%) were asymptomatic, and these differences were statistically significant ( $p < .000$ ) (Figure 3). To assess the association between Ct values and risk factors, the studied patients were categorized into three Ct value groups: low ( $\leq 24$ ), medium (25-30), and high ( $> 30$ ) groups. The frequency of low, medium, and high Ct values was 45.1% ( $n = 129$ ), 30.8% ( $n = 88$ ), and 24.1% ( $n = 69$ ), respectively.

**Table 2)** Frequency distribution of COVID-19 patients by age

| Age Groups            | No. of Cases | Percent (%) |
|-----------------------|--------------|-------------|
| Pediatrics: $\leq 17$ | 6            | 2.1         |
| Adults: 18-40         | 61           | 21.3        |
| Middle-aged: 41-60    | 166          | 58.1        |
| Elderly: $\geq 61$    | 53           | 18.5        |
| Total                 | 286          | 100         |




**Figure 1)** Frequency distribution of COVID-19 patients based on symptoms

The correlation between Ct values and gender was not significant ( $p = .093$ ). However, the majority of elderly patients (66%) were in the low Ct value group, while patients in the other age groups were equally distributed across the three Ct value categories. A statistically significant relationship was found between Ct values and age groups ( $p = .023$ ).

This study demonstrated a significant association between symptomatic presentation and lower Ct values, with

**Table 3)** Comorbidities of the COVID-19 patients

| Comorbidities diseases                    | No. of patients | Percentage (%) |
|---|-----------------|----------------|
| Asthma                                    | 55              | 19.2           |
| Cancer                                    | 14              | 4.9            |
| Cerebrovascular accident (CVA)            | 3               | 1.0            |
| Diabetes mellitus (DM)                    | 44              | 15.4           |
| Diabetes mellitus + hypertension (DM+HTN) | 33              | 11.5           |
| Hypertension (HTN)                        | 37              | 12.9           |
| Ischemic heart disease (IHD)              | 17              | 5.9            |
| Kidney failure                            | 5               | 1.7            |
| No  | 78              | 27.3           |
| Total                                     | 286             | 100.0          |



**Figure 2)** Distribution of symptoms in different age groups




Figure 3) Distribution of symptoms based of different chronic diseases

Table 4) Association of Ct values with age, gender, blood groups, and comorbidities of the study participants

| Risk Factors                 | Categories                                | Low Ct Value (≤24)<br>N (%) | Medium Ct Value (25-30)<br>N (%) | High Ct Value (>30)<br>N (%) | Total Cases | P-Value |
|------------------------------|---|-----------------------------|----------------------------------|------------------------------|-------------|---------|
| Age groups                   | ≤17                                       | 2 (33.3)                    | 2 (33.3)                         | 2 (33.3)                     | 6           | 0.023   |
|                              | 18-40                                     | 20 (32.8)                   | 21 (34.4)                        | 20 (32.8)                    | 61          |         |
|                              | 41-60                                     | 72 (34.4)                   | 53 (31.9)                        | 41 (24.7)                    | 166         |         |
|                              | ≥61                                       | 35 (66.0)                   | 12 (22.4)                        | 6 (11.3)                     | 53          |         |
| Gender                       | Male                                      | 69 (51.9)                   | 37 (27.8)                        | 27 (20.3)                    | 133         | 0.093   |
|                              | Female                                    | 60 (39.2)                   | 51 (33.3)                        | 42 (27.5)                    | 153         |         |
| Underlying medical condition | Asthma                                    | 19 (34.5)                   | 25 (45.5)                        | 11 (20)                      | 55          | 0.000   |
|                              | Cancer                                    | 9 (64.3)                    | 4 (28.6)                         | 1 (7.1)                      | 14          |         |
|                              | Cerebrovascular accident (CVA)            | 3 (100)                     | 0                                | 0                            | 3           |         |
|                              | Diabetes mellitus (DM)                    | 27 (61.4)                   | 14 (31.8)                        | 3 (6.8)                      | 44          |         |
|                              | Diabetes mellitus + Hypertension (DM+HTN) | 24 (72.7)                   | 7 (21.2)                         | 2 (6.1)                      | 33          |         |
|                              | Hypertension (HTN)                        | 22 (59.5)                   | 11 (29.7)                        | 4 (10.8)                     | 37          |         |
|                              | Ischemic heart disease (IHD)              | 9 (52.9)                    | 6 (35.3)                         | 2 (11.8)                     | 17          |         |
|                              | Kidney failure                            | 3 (60)                      | 2 (40)                           | 0                            | 5           |         |
| Symptom status               | No  | 13 (16.7)                   | 19 (24.3)                        | 46 (59)                      | 78          | 0.000   |
|                              | Severe symptoms                           | 95 (64.6)                   | 42 (28.6)                        | 10 (6.8)                     | 147         |         |
|                              | Moderate symptoms                         | 31 (40.8)                   | 33 (43.4)                        | 12 (15.8)                    | 76          |         |
| Blood groups                 | Asymptomatic                              | 3 (4.8)                     | 13 (20.6)                        | 47 (74.6)                    | 63          | 0.000   |
|                              | A   | 53 (64.6)                   | 24 (29.3)                        | 5 (6.1)                      | 82          |         |
|                              | B   | 39 (47)                     | 37 (44.6)                        | 7 (8.4)                      | 83          |         |
|                              | AB  | 31 (62)                     | 16 (32)                          | 3 (6)                        | 50          |         |
|                              | O   | 6 (8.5)                     | 11 (1.4)                         | 54 (76.1)                    | 71          |         |

severe disease found to be significantly correlated with lower Ct values ( $p = .000$ ). Regarding the association between Ct values and blood groups, the majority of patients with blood groups A (64.6%) and AB (62%) were in the low Ct value category, whereas most of the patients with blood group O (76.1%) were in the high Ct value category, and this difference was statistically significant ( $p = .000$ ) (Table 4).

This study also found a significant association between lower Ct values and the presence of comorbidities such as hypertension, diabetes mellitus, ischemic heart disease (IHD), cerebrovascular accident, and cancer ( $p = .000$ ).

### Discussion

Ghadamis hospital is located in Ghadames, a city in the western part of Libya, connected to the capital, Tripoli, where approximately 3 million people live. The prevalence rate of SARS-CoV-2 (COVID-19) in this region has been documented as 18.6% per 100,000 inhabitants. Additionally, the testing rate during the COVID-19 pandemic was 5 per 100,000 people per week, which is considered inadequate testing at the national level [12].

In this study, the association between rRT-PCR Ct values and demographic and clinical characteristics of COVID-19 patients was investigated to determine whether Ct values could serve as an important marker for predicting the severity of COVID-19 disease in hospitalized COVID-19 individuals.

There are limited studies using RT-PCR Ct values to quantify SARS-CoV-2 RNA in clinical samples in our region. This is the first study conducted to examine the relationship between RT-PCR Ct values and severity of COVID-19 in Libya.

A total of 286 COVID-19 patients were included in this investigation. Most of the COVID-19 patients were female (53.5%).

This female predominance has also been reported in other studies [11]. These results are in contradiction with the results of a similar study in India [13], where males were more likely to be infected with COVID-19 than females.

In this study, the majority of positive cases (58%) were in the middle-aged group (41-60 years), followed by adults (18-40 years, 21.3%) and the elderly population ( $\geq 61$  years, 18.5%). In an Indian study, adults aged 18-40 years comprised the largest proportion of positive patients (45%), followed by the elderly (41%), while pediatric and geriatric populations were the least affected groups [13].

Regarding symptoms, 78% of the patients were symptomatic, with 66% experiencing severe symptoms, while 22% were asymptomatic. These findings are in agreement with the results reported in England (19%) [14] and China (29.4%) [15], showing a lower percentage of asymptomatic cases. In contrast, the percentage of asymptomatic cases (43%) was reported to be high in the United Arab Emirates (UAE) [16]. The increased number of asymptomatic COVID-19 cases in the UAE has been attributed to extensive active tracing and screening efforts implemented by health authorities.

A significant portion of the population may be asymptomatic, which could contribute to the effective spread of the infection without being detected by testing or requiring medical intervention.

Regarding the significant association between the severity of COVID-19 and older age groups (41-60 and  $\geq 61$  years) as well as individuals with chronic comorbidities, older individuals are generally less healthy and often have underlying conditions such as diabetes mellitus and hypertension. Additionally, older populations are less likely to be engaged in physical activities

(e.g., sports, walking) and may be retired or unemployed. These suggest that age, chronic comorbidities, and overall health status of populations play a critical role in the incidence of moderate and severe forms of COVID-19.

The median Ct value of SARS-CoV-2 RNA in this study was 25 (range: 12-40) among COVID-19 patients. Also, a study in Turkey reported a median Ct value of 28.16 (range: 24.5-31.6) for hospitalized patients [17]. Another study by Kleiboeker et al. (2020) Kleiboeker, Cowden [18] studied the RT-PCR results of more than 4000 COVID-19 samples and reported Ct values in the range of 6.16–37.92.

This study findings revealed that the frequency of low, medium, and high Ct values (indicating high, moderate, and low viral loads) was 45.1, 30.8, and 24.1%, respectively. Ct values inversely serve as a representative marker of viral load. A higher viral load is indicated by a lower Ct value and vice versa [19]. Li, Zeng [20] documented that higher viral loads were associated with severe disease, with viral loads being higher during the initial stages of the illness. Magleby [21] confirmed that higher viral load was linked with older age, existing medical conditions, smoking, and recently administered chemotherapy.

In this study, the majority of middle-aged and elderly subjects (40-60 and  $\geq 61$  years) exhibited low Ct values compared to the adult and pediatric populations. These findings are consistent with other research indicating lower Ct values in older COVID-19 patients compared to younger individuals, suggesting higher viral loads [22, 23]. However, a study by George, Murugan [13] found that the majority of pediatric, adult (18-40 years), and middle-aged patients (40-60 years) exhibited low Ct values, while the older group primarily displayed median Ct value. This study also identified a significant

association between lower Ct values and symptomatic presentation and disease severity. Symptomatic COVID-19 cases were notably linked with lower Ct values, indicating elevated viral load and prolonged viral shedding, which may influence the disease spread and contagiousness [24]. Similar studies have also revealed that symptomatic patients tend to have lower Ct values (higher viral loads) [24-26].

In this study, the results showed that low Ct values were the most prevalent, followed by medium and high Ct values. The findings indicated that a significant proportion of non-severe patients with mild symptoms (41%, 31 of 76) also had low Ct values. These results indicate the important role of non-severe COVID-19 patients in the spread of the disease regardless of their symptomatic status.

Interestingly, a significant association was found between lower Ct values (indicating high viral loads) and the presence of comorbidities such as hypertension, diabetes mellitus, cerebrovascular accident, and cancer. The existence of comorbidities such as hypertension, asthma, diabetes mellitus, and cancer is known to be linked with worse outcomes in COVID-19 patients [27, 28]. These individuals might have a reduction in cardiopulmonary capacity, making them vulnerable to the physiologic challenges caused by COVID-19 [4]. Several factors affect the Ct values of SARS-CoV-2 positive samples, including pre-analytical and analytical factors such as sample collection, transportation, and storage, RNA extraction, gene targets, PCR sensitivity, amplification range, and techniques used.

## Conclusion

The majority of COVID-19 cases identified in Libya between August 2020 and August 2021 were symptomatic, with a significant portion of asymptomatic cases being

children. In this study, the majority of older individuals showed lower Ct values (indicating a high viral load) compared to the adult and pediatric populations. Symptomatic patients exhibited notably low Ct values, indicating their important role in the spread of COVID-19. A significant association was found between high viral loads and the presence of comorbidities in patients. Low Ct values were also observed in non-severe patients with mild symptoms (moderate), suggesting their crucial role in SARS-CoV-2 spread regardless of their symptomatic status. Identifying low Ct values and quarantining patients with mild symptoms are essential measures to prevent COVID-19 transmission. These findings emphasize the crucial role of viral load in SARS-CoV-2 pathogenesis and indicate that Ct values in positive COVID-19 cases could be used to predict the spread of infection in the community.

### Acknowledgements

None declared by authors.

**Ethical permissions:** Not applicable.

**Authors' Contributions:** Ghassan Tayh analyzed data, interpreted results, wrote and edited the manuscript. Asma Elramli contributed to writing the practical aspect and data entry. Siham Agouri participated in editing the manuscript. Elmundr Abughnia participated in performing the experimental part of the manuscript. Naila Y. Abdulrahman collected samples. Abdulghafar A. Shihab collected samples. Hafsa A. Alemam designed and supervised the study.

**Conflicts of Interests:** The authors declare that they have no conflicts of interest.

**Fundings:** No funding.

**Consent to participate:** Not applicable.

### References

1. Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI-P, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-

- nCoV): a systematic review. *Journal of clinical medicine*. 2020;9(3):623.
2. Machado BAS, Hodel KVS, Barbosa-Júnior VG, Soares MBP, Badaró R. The main molecular and serological methods for diagnosing COVID-19: an overview based on the literature. *Viruses*. 2020;13(1):40.
3. Shenoy S. SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: a systematic review. *World Journal of Critical Care Medicine*. 2021;10(4):132.
4. Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, et al. Impact of severe acute respiratory syndrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. *Clinical infectious diseases*. 2021;73(11):e4197-e205.
5. Ramirez-Hinojosa JP, Rodriguez-Sanchez Y, Romero-Gonzalez AK, Chavez-Gutierrez M, Gonzalez-Arenas NR, Ibarra-Arce A, et al. Association between cycle threshold (Ct) values and clinical and laboratory data in inpatients with COVID-19 and asymptomatic health workers. *Journal of medical virology*. 2021;93(10):5969-76.
6. Waudby-West R, Parcell BJ, Palmer CN, Bell S, Chalmers JD, Siddiqui MK. The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort. *European Respiratory Journal*. 2021;58(1).
7. Shah VP, Farah WH, Hill JC, Hassett LC, Binnicker MJ, Yao JD, et al., editors. Association between SARS-CoV-2 cycle threshold values and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. *Open Forum Infectious Diseases*; 2021: Oxford University Press US.
8. Sala E, Shah IS, Manissero D, Juanola-Falgarona M, Quirke A-M, Rao SN. Systematic review on the correlation between SARS-CoV-2 real-time PCR cycle threshold values and epidemiological trends. *Infectious Diseases and Therapy*. 2023;12(3):749-75.
9. Yin N, Dellicour S, Daubie V, Franco N, Wautier M, Faes C, et al. Leveraging of SARS-CoV-2 PCR cycle thresholds values to forecast COVID-19 trends. *Frontiers in medicine*. 2021;8:743988.
10. Penney JA, Jung AW, Koethe BC, Doron SI. Utility of the cycle threshold in anticipating the next phase of the coronavirus disease 2019 (COVID-19) pandemic. *Infection Control & Hospital Epidemiology*. 2022;43(6):800-1.
11. Lippi G, Plebani M. The many clinical advantages of reporting the cycle threshold (Ct) value. *Annals of Translational Medicine*. 2022;10(7):427-.
12. WHO. Libya COVID-19 Surveillance Weekly Bulletin: Epidemiological Week 33 (15 – 21



- August 2022): World Health Organization; 2022 [
13. George A, Murugan T, Sampath S, Madhusudhan N, Thamizharasi M, SAMPATH S. Epidemiology of COVID-19 and the Utility of Cycle Threshold (Ct) Values in Predicting the Severity of Disease. *Cureus*. 2023;15(8).
  14. Wells PM, Doores KJ, Couvreur S, Nunez RM, Seow J, Graham C, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. *Journal of Infection*. 2020;81(6):931-6.
  15. Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic and symptomatic patients with non-severe coronavirus disease (COVID-19) have similar clinical features and virological courses: a retrospective single center study. *Frontiers in microbiology*. 2020;11:1570.
  16. Al-Rifai RH, Acuna J, Al Hossany FI, Aden B, Al Memari SA, Al Mazrouei SK, et al. Epidemiological characterization of symptomatic and asymptomatic COVID-19 cases and positivity in subsequent RT-PCR tests in the United Arab Emirates. *PLoS One*. 2021;16(2):e0246903.
  17. Yagci AK, Sarinoglu RC, Bilgin H, Yanilmaz Ö, Sayin E, Deniz G, et al. Relationship of the cycle threshold values of SARS-CoV-2 polymerase chain reaction and total severity score of computerized tomography in patients with COVID 19. *International Journal of Infectious Diseases*. 2020;101:160-6.
  18. Kleiboeker S, Cowden S, Grantham J, Nutt J, Tyler A, Berg A, et al. SARS-CoV-2 viral load assessment in respiratory samples. *Journal of Clinical Virology*. 2020;129:104439.
  19. Rao SN, Manissero D, Steele VR, Pareja J. A narrative systematic review of the clinical utility of cycle threshold values in the context of COVID-19. *Infectious diseases and therapy*. 2020;9:573-86.
  20. Li Z, Zeng B, Lei P, Liu J, Fan B, Shen Q, et al. Differentiating pneumonia with and without COVID-19 using chest CT images: from qualitative to quantitative. *Journal of X-ray Science and Technology*. 2020;28(4):583-9.
  21. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020.
  22. Maltezou HC, Raftopoulos V, Vorou R, Papadima K, Mellou K, Spanakis N, et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. *The Journal of infectious diseases*. 2021;223(7):1132-8.
  23. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet infectious diseases*. 2020;20(5):565-74.
  24. Abdulrahman A, Mallah SI, Alawadhi A, Perna S, Janahi EM, AlQahtani MM. Association between RT-PCR Ct values and COVID-19 new daily cases: a multicenter cross-sectional study. *Le Infezioni in Medicina*. 2021;29(3):416.
  25. Kociolek LK, Muller WJ, Yee R, Dien Bard J, Brown CA, Revell PA, et al. Comparison of upper respiratory viral load distributions in asymptomatic and symptomatic children diagnosed with SARS-CoV-2 infection in pediatric hospital testing programs. *Journal of clinical microbiology*. 2020;59(1):10.1128/jcm. 02593-20.
  26. Han MS, Seong M-W, Kim N, Shin S, Im Cho S, Park H, et al. Viral RNA load in mildly symptomatic and asymptomatic children with COVID-19, Seoul, South Korea. *Emerging infectious diseases*. 2020;26(10):2497.
  27. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA internal medicine*. 2020;180(7):934-43.
  28. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *The lancet oncology*. 2020;21(3):335-7.